ChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $1.88

ChromaDex Co. (NASDAQ:CDXC) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.88 and traded as high as $3.72. ChromaDex shares last traded at $2.95, with a volume of 877,796 shares traded.

Wall Street Analysts Forecast Growth

CDXC has been the subject of several recent research reports. Roth Mkm increased their target price on shares of ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. StockNews.com initiated coverage on shares of ChromaDex in a report on Sunday, March 3rd. They set a “strong-buy” rating for the company.

ChromaDex Stock Down 20.1 %

The company’s fifty day moving average is $2.74 and its 200 day moving average is $1.88. The firm has a market cap of $222.16 million, a price-to-earnings ratio of -42.14 and a beta of 1.98.

Institutional Trading of ChromaDex

A number of large investors have recently added to or reduced their stakes in the company. Tieton Capital Management LLC lifted its stake in ChromaDex by 18.8% in the fourth quarter. Tieton Capital Management LLC now owns 2,913,675 shares of the company’s stock valued at $4,167,000 after acquiring an additional 461,692 shares during the last quarter. International Assets Investment Management LLC lifted its stake in ChromaDex by 43.0% in the fourth quarter. International Assets Investment Management LLC now owns 28,600 shares of the company’s stock valued at $410,000 after acquiring an additional 8,600 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in ChromaDex in the fourth quarter valued at $118,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ChromaDex by 121.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after acquiring an additional 45,618 shares during the last quarter. Finally, Gabelli Funds LLC lifted its stake in ChromaDex by 9.1% in the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock valued at $263,000 after acquiring an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.